

ARGENX SE

ISIN: **NL0010832176** WKN: -

Overview

2024/07/09 15:30:43

Price
410.30 EUR

Difference ▲ 1.84% (7.40)

| General attributes | |
|--------------------|------------------------------------|
| ISIN | NL0010832176 |
| Symbol | ARGX |
| Exchange | Vienna Stock Exchange |
| Currency | EUR |
| Sector | Chemical / Pharmaceutical / Health |
| Security type | Stock |
| Market cap (m) | 24,723 EUR |
| Benchmark | AMSTERDAM EXCHANGES INDEX |

| Market data | |
|-------------------|-----------------|
| Bid (Bid size) | 423.60 EUR (46) |
| Ask (Ask size) | 426.30 EUR (24) |
| Open | 405.90 EUR |
| High | 412.40 EUR |
| Low | 405.90 EUR |
| Close (prev. day) | 402.90 EUR |
| VWAP | 356.20 EUR |
| Volume (pcs) | 0 |
| Trading volume | 0.00 |
| Number of trades | 4 |
| Last size | 0 |

| Futures and Options | |
|---------------------|----|
| Related Futures | 24 |
| Related Options | - |

PDF Downloads

Company report: ARGENX SE 



Information about previous performance does not guarantee future performance.
Source: FactSet

Recent research

| on sector | on market | | |
|------------|---|-----------------------|---|
| Date | | Headline | Download |
| 2024/06/21 |  | Global Equity Ratings |  |
| 2024/06/14 |  | Global Equity Ratings |  |
| 2024/05/29 |  | Global Equity Ratings |  |
| 2024/04/26 |  | Global Equity Ratings |  |
| 2024/04/03 |  | Global Equity Ratings |  |

Details

2024/07/09 15:30:43

Price

410.30 EUR

Difference ▲ 1.84% (7.40)

General attributes

ISIN NL0010832176

Symbol ARGX

Exchange Vienna Stock Exchange

Currency EUR

Sector Chemical / Pharmaceutical / Health

Security type Stock

Market cap (m) 24,723 EUR

Benchmark AMSTERDAM EXCHANGES INDEX

Market data

Bid (Bid size) 423.60 EUR (46)

Ask (Ask size) 426.30 EUR (24)

Open 405.90 EUR

High 412.40 EUR

Low 405.90 EUR

Close (prev. day) 402.90 EUR

VWAP 356.20 EUR

Volume (pcs) 0

Trading volume 0.00

Number of trades 4

Last size 0

Performance and Risk

| | 6m | 1Y | 3Y |
|-------------|--------|---------|---------|
| Perf (%) | +9.79% | +17.26% | +56.36% |
| Perf (abs.) | +36.60 | +60.40 | +147.90 |
| Beta | 0.71 | 0.31 | 0.41 |
| Volatility | 45.45 | 69.29 | 51.78 |



Information about previous performance does not guarantee future performance.
Source: FactSet

Price data

| | |
|---|-------------------------|
| Ø price 5 days Ø volume 5 days (pcs.) | 406.80 EUR (0) |
| Ø price 30 days Ø volume 30 days (pcs.) | 375.49 EUR (0) |
| Ø price 100 days Ø volume 100 days (pcs.) | 360.92 EUR (2) |
| Ø price 250 days Ø volume 250 days (pcs.) | 392.87 EUR (1) |
| YTD High date | 425.60 EUR (2024/06/26) |
| YTD Low date | 329.20 EUR (2024/05/22) |
| 52 Weeks High date | 486.30 EUR (2023/09/18) |
| 52 Weeks Low date | 303.50 EUR (2023/12/21) |

All listings for ARGENX SE

| Exchange 📍 | Date | Time | Price | Trading volume (mio.) | Number of trades |
|-------------------------|------------|-------|------------|-----------------------|------------------|
| Vienna Stock Exchange | 2024/07/09 | 15:30 | 410.30 EUR | 0.00 | 4 |
| Tradegate | 2024/07/10 | 11:20 | 421.50 EUR | 0.00 | 1 |
| Stuttgart | 2024/07/10 | 13:30 | 423.10 EUR | 0.00 | 5 |
| Munich | 2024/07/10 | 08:09 | 420.70 EUR | 0.00 | 1 |
| London Stock Exchange | 2024/07/10 | 08:59 | 420.00 EUR | 0.00 | 1 |

| | | | | | | |
|---|----------------|-------|--------|-----|------|-------|
| European Trade Reporting | 07/10 | | | | | |
| Frankfurt | 2024/ 07/10 | 11:19 | 422.00 | EUR | 0.00 | 2 |
| FINRA other OTC Issues | 2024/ 05/06 | 16:38 | 373.50 | USD | 0.01 | 2 |
| Euronext Milan MTF Trading After Hours | - | - | - | | 0.00 | - |
| Euronext Brussels | 2024/ 07/10 | 14:54 | 424.90 | EUR | 5.95 | 1,004 |
| Duesseldorf | 2024/ 07/10 | 08:12 | 420.80 | EUR | 0.00 | 1 |
| Berlin | 2024/ 07/10 | 14:15 | 425.30 | EUR | 0.00 | 9 |

Company profile

Company Logo



Contact Details

ARGENX SE

--

Laarderhoogtweg 25 - 1101 EB Amsterdam

Telefon: +31-76-303-04-88

Fax: +

E-mail: info@argenx.com

PDF Downloads

Company report: ARGENX SE



Company Profile

argenx SE is a global immunology company, which engages in improving the lives of people suffering from severe autoimmune diseases. It operates through the following geographical segments: United States, Japan, EMEA, and China. The company was founded by Hans J. W. de Haard, Torsten Dreier, and Tim van Hauwermeiren in 2008 and is headquartered in Amsterdam, the Netherlands.

Members of Management Board

Tim Van Hauwermeiren Chairman of Managing Board

Andria Wilk Member of Executive Committee

Arjen Lemmen Member of Executive Committee

Beth DelGiacco Member of Executive Committee

Filip Borgions Member of Executive Committee

Karen Massey Member of Executive Committee

Karl Gubitz Member of Executive Committee

Luc Truyen Member of Executive Committee

Malini Moorthy Member of Executive Committee

Marc Schorpion Member of Executive Committee

Peter Ulrichs Member of Executive Committee

Board of directors

Peter K. M. Verhaeghe Chairman of Supervisory Board

Ana Cespedes Member of Supervisory Board

Brian Kotzin Member of Supervisory Board

Joseph deBethizy Member of Supervisory Board

Pamela Klein Member of Supervisory Board

Anthony Adam Rosenberg Member of Supervisory Board

Camilla Sylvest Member of Supervisory Board

James Daly Member of Supervisory Board

Steve Krognos Member of Supervisory Board